Don’t Trust Reclast Infusion—This Risk is Too Real to Ignore

Mon, 04 May 2026 10:01:53 +0000

Don’t Trust Reclast Infusion—The Hidden Risk You Need to Know About When it comes to managing severe osteoporosis, Reclast (olithic acid, or ipandronate) has long been a widely prescribed treatment. Marketed as a powerful bisphosphonate that slows bone loss, Reclast has helped millions preserve bone density and reduce fracture risks. However, recent concerns are emerging that demand urgent attention—Don’t trust Reclast infusion without understanding the serious risks it may pose. ### What Is Reclast Infusion? Reclast is a third-generation bisphosphonate administered intravenously, primarily used to treat osteoporosis and reduce the risk of spinal, hip, and other fractures in postmenopausal women and men at high risk. While it strengthens bones by inhibiting osteoclast activity—the cells responsible for bone resorption—Manufacturers and healthcare providers have begun acknowledging that the risks beyond its benefits may not be as clear-cut as once thought.